Next 10 |
home / stock / axsm / axsm articles
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company developing and deliver...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel...
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel...
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel ...
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel ...
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 0.5% on Tuesday. Shares of Hello Group Inc. (NASDAQ:MOMO...
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel ...
AXS-05 in Alzheimer's disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in poole...
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering nove...
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
2024-06-27 09:42:00 ET There are things that can affect and sink the stock prices of companies in most industries. One of them is a short-seller report. Axsome Therapeutics (NASDAQ: AXSM) , a mid-cap biotech, was recently the target of one, and it already wasn't having a great year ...
2024-06-11 16:30:03 ET Guggenheim analyst issues BUY recommendation for AXSM on June 11, 2024 03:28PM ET. The previous analyst recommendation was Buy. AXSM was trading at $71.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...